Drug General Information (ID: DDICJ9DBRH)
Drug Name			Iodine (topical)		Drug Info		Iodide I-123		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Nutritional Supplements				Diagnostic Radiopharmaceuticals
Structure

Mechanism of Iodine (topical)-Iodide I-123 Interaction (Severity Level: Moderate)
Interference of cell/tissue uptake Click to Show/Hide Mechanism Graph
Drug Name		Iodine (topical)				Iodide I-123
Mechanism		Interfere with the therapeutic effect and/or diagnostic result of radioiodides				Radioiodide
Key Mechanism Factor 1
		Factor Name		Pharmacokinetics
		Factor Description		Alters the distribution of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects.
Mechanism Description		Interference of cell/tissue uptake of Iodide I-123 by Iodine (topical)

Recommended Action
Management		Iodine preparations including expectorants, vitamins, topicals, and intravascular iodine-containing contrast media should be withheld for at least 2 to 4 weeks and possibly longer, and cholecystographic agents should be withheld for more than 4 weeks, prior to administration of sodium iodide I-131 or I-123.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Product Information. Sodium Iodide I-123 (sodium iodide I-123). GE Healthcare, Princeton, NJ.
3	Product Information. Visipaque (iodixanol). Nycomed Inc, Princeton, NJ.